Future efforts to develop GSH inhibitors specific for GCLC may still prove clinically useful in some contexts, particularly in combination with thioredoxin inhibitors in cancer settings and in combination with anti-parasitic agents in African sleeping sickness and other Trypanosome diseases, which BSO has shown some promise in treating (60, 61). The gene discussed is TXN; the disease is human African trypanosomiasis.